The three main characteristics of MS are the formation of lesions in the central nervous system (also called plaques), inflammation, and the destruction of myelin sheaths of neurons. These features interact in a complex and not yet fully understood manner to produce the breakdown of nerve tissue, and in turn, the signs and symptoms of the disease.[1] MS is believed to be an immune-mediated disorder that develops from an interaction of the individual's genetics and as yet unidentified environmental causes.[2] Damage is believed to be caused, at least in part, by attack on the nervous system by a person's own immune system.[1]
Immune Dysregulation
editAs briefly detailed in the causes section of this article, MS is currently thought to stem from a failure of the body's immune system to kill off autoreactive T-cells & B-cells.[3] Currently, the T-cell subpopulations that are thought to drive the development of MS are autoreactive CD8+ T-cells, CD4+ helper T-cells, and TH17 cells.[4] These autoreactive T-cells produce substances called cytokines that induce an inflammatory immune response in the CNS, leading to the development of the disease.[5] More recently, however, the role of autoreactive B-cells has been elucidated. Evidence of their contribution to the development of MS is implicated through the presence of oligoclonal IgG bands (antibodies produced by B-cells) in the CSF of patients with MS.[6][7] The presence of these oligoclonal bands has been used as supportive evidence in clinching a diagnosis of MS.[8] As similarly described before, B-cells can also produce cytokines that induce an inflammatory immune response via activation of autoreactive T-cells.[9] As such, higher levels of these autoreactive B-cells is associated with increased number of lesions & neurodegeneration as well as worse disability.[10]
Another cell population that is becoming increasingly implicated in MS are microglia. These cells are resident to & keep watch over the CNS, responding to pathogens by shifting between pro- & anti-inflammatory states.[11] Microglia have been shown to be involved in the formation of MS lesions and have been shown to be involved in other diseases that primarily affect the CNS white matter.[12] Although, because of their ability to switch between pro- & anti-inflammatory states, microglia have also been shown to be able to assist in remyelination & subsequent neuron repair.[13] As such, microglia are thought to be participating in both acute & chronic MS lesions, with 40% of phagocytic cells in early active MS lesions being proinflammatory microglia.[14]
Lesions
editThe name multiple sclerosis refers to the scars (sclerae – better known as plaques or lesions) that form in the nervous system. These lesions most commonly affect the white matter in the optic nerve, brain stem, basal ganglia, and spinal cord, or white matter tracts close to the lateral ventricles.[1] The function of white matter cells is to carry signals between grey matter areas, where the processing is done, and the rest of the body. The peripheral nervous system is rarely involved.[2]
To be specific, MS involves the loss of oligodendrocytes, the cells responsible for creating and maintaining a fatty layer—known as the myelin sheath—which helps the neurons carry electrical signals (action potentials).[1] This results in a thinning or complete loss of myelin, and as the disease advances, the breakdown of the axons of neurons. When the myelin is lost, a neuron can no longer effectively conduct electrical signals.[2] A repair process, called remyelination, takes place in early phases of the disease, but the oligodendrocytes are unable to completely rebuild the cell's myelin sheath.[15] Repeated attacks lead to successively less effective remyelinations, until a scar-like plaque is built up around the damaged axons.[15] These scars are the origin of the symptoms and during an attack magnetic resonance imaging (MRI) often shows more than 10 new plaques.[1] This could indicate that some number of lesions exist, below which the brain is capable of repairing itself without producing noticeable consequences.[1] Another process involved in the creation of lesions is an abnormal increase in the number of astrocytes due to the destruction of nearby neurons.[1] A number of lesion patterns have been described.[16]
Inflammation
editApart from demyelination, the other sign of the disease is inflammation. Fitting with an immunological explanation, the inflammatory process is caused by T cells, a kind of lymphocytes that plays an important role in the body's defenses.[2] T cells gain entry into the brain as a result of disruptions in the blood–brain barrier. The T cells recognize myelin as foreign and attack it, explaining why these cells are also called "autoreactive lymphocytes".[1]
The attack on myelin starts inflammatory processes, which trigger other immune cells and the release of soluble factors like cytokines and antibodies. A further breakdown of the blood-brain barrier, in turn, causes a number of other damaging effects, such as swelling, activation of macrophages, and more activation of cytokines and other destructive proteins.[2] Inflammation can potentially reduce transmission of information between neurons in at least three ways.[1] The soluble factors released might stop neurotransmission by intact neurons. These factors could lead to or enhance the loss of myelin, or they may cause the axon to break down completely.[1]
Blood–brain barrier
editThe blood–brain barrier (BBB) is a part of the capillary system that prevents the entry of T cells into the central nervous system. It may become permeable to these types of cells secondary to an infection by a virus or bacteria. After it repairs itself, typically once the infection has cleared, T cells may remain trapped inside the brain.[2][17] Gadolinium cannot cross a normal BBB, so gadolinium-enhanced MRI is used to show BBB breakdowns.[18]
This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft
editLead
editArticle body
editReferences
edit- ^ a b c d e f g h i j Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–1517. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
- ^ a b c d e f Compston A, Coles A (April 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–1231. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
- ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ McGinley, Marisa P.; Goldschmidt, Carolyn H.; Rae-Grant, Alexander D. (2021-02-23). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765. doi:10.1001/jama.2020.26858. ISSN 0098-7484.
- ^ Thompson, Alan J; Banwell, Brenda L; Barkhof, Frederik; Carroll, William M; Coetzee, Timothy; Comi, Giancarlo; Correale, Jorge; Fazekas, Franz; Filippi, Massimo; Freedman, Mark S; Fujihara, Kazuo; Galetta, Steven L; Hartung, Hans Peter; Kappos, Ludwig; Lublin, Fred D (2018-02). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet Neurology. 17 (2): 162–173. doi:10.1016/s1474-4422(17)30470-2. ISSN 1474-4422.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Ward, Melanie; Goldman, Myla D. (2022-08). "Epidemiology and Pathophysiology of Multiple Sclerosis". CONTINUUM: Lifelong Learning in Neurology. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. ISSN 1538-6899.
{{cite journal}}
: Check date values in:|date=
(help) - ^ a b Chari DM (2007). "Remyelination in multiple sclerosis". International Review of Neurobiology. 79: 589–620. doi:10.1016/S0074-7742(07)79026-8. ISBN 978-0-12-373736-6. PMC 7112255. PMID 17531860.
- ^ Pittock SJ, Lucchinetti CF (March 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
- ^ Huang X, Hussain B, Chang J (January 2021). "Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms". CNS Neuroscience & Therapeutics. 27 (1): 36–47. doi:10.1111/cns.13569. PMC 7804893. PMID 33381913.
- ^ Ferré JC, Shiroishi MS, Law M (November 2012). "Advanced techniques using contrast media in neuroimaging". Magnetic Resonance Imaging Clinics of North America. 20 (4): 699–713. doi:10.1016/j.mric.2012.07.007. PMC 3479680. PMID 23088946.